Investigator-Sponsored Studies (ISS)
Investigator-Sponsored Studies (ISS)
Y-mAbs recognizes the importance of independent clinical and scientific research in advancing medicine. We are therefore supportive of high standard ethical research conducted by external sponsors that aligns with our scientific areas of interest and advances knowledge about our products and disease areas to enhance patient care.
Investigator Sponsored Studies (ISS) are clinical or pre-clinical studies that are entirely sponsored, designed and managed by an external sponsor.
The support provided by Y-mabs can be in the form of product and/or funding.
Researchers may submit their concept research proposal via the submission portal. If the concept proposal is aligned to areas of scientific interest, an initial approval in principle may be followed by a request for more detailed submission.
A full submission must be received to be considered for final approval.
ISS Proposal Submission Portal
ISS Areas of Interest
Neuroblastoma
- Studies to advance care of patients with alternative administration (dose, schedule, infusion) of naxitamab and AE management
- Studies to advance the understanding of naxitamab in combination treatment with chemotherapy or other novel therapies (e.g. DFMO, other monoclonal antibodies, tyrosine kinase inhibitors, cellular therapy)
- In combination with chemotherapy in the induction, consolidation, or bridge to transplant setting
Osteosarcoma
- Front line setting combination treatment
- Refractory disease
- Incomplete resection in patients with relapsed disease
Soft-tissue sarcomas
- Newly diagnosed patients – front-line therapy
- First relapse combination treatment
Melanoma
- Clinical research in the areas of unmet medical need
- Translational research
Other areas of interest
- Triple-negative breast Cancer (TNBC)
- Small Cell Lung Cancer (SCLC)
- Ewing Sarcoma
- Retinoblastoma